I have taught at Université Paris Ouest Nanterre La Défense on a number of occasions but I continue to be impressed by the enthusiasm and challenging questions the Master’s level students pose. Paris is rich with culture and the education system has many benefits. I am privileged to be part of a growing French research culture that respects skills and knowledge with cutting edge technology in neuroscience.
Eiffel Tower, roof-top.
This complements my experience at Bournemouth University and has enabled me to collaborate on projects that face difficult challenges with respect to ethics and use of expensive technology, namely fMRI scanning. Functional Magnetic Resonance Scanning is notoriously expensive yet the benefits to clinical research are potentially huge.
My study on yawning and cortisol at Bournemouth University [1] has now includes collaboration with three prestigious centres in France: Université Paris Ouest Nanterre La Défense, Amiens University Hospital, University of Picardy Jules Verne.
I hope to continue my Anglo-French meetings with the assistance of the Erasmus Travel Scholarship scheme in the future, as well as with funding from the French Embassy and the French Multiple Sclerosis Society.
[1] Thompson, S.B.N., 2014. Yawning, fatigue and cortisol: expanding the Thompson Cortisol Hypothesis. Medical Hypotheses. Doi: 10.1016/j.mehy.2014.08.009.













BU academics publish in Nepal national newspaper
New BU Physiology paper
Gender and street names
Help Shape the Future of Research at BU: Postgraduate Research Experience Survey 2026 Now Open
3C Event: Research Culture, Community & Cherry Blossom – Tuesday 14 April
REMINDER: 3MT® Competition – Deadline 9am Monday 20 April
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease